share_log
Benzinga ·  05/01 06:38

Kalvista Pharmaceuticals Announced Its Strategic Plans For Fiscal Year 2025, Beginning May 1, Including For Sebetralstat, The Company's Investigational Novel, Oral Plasma Kallikrein Inhibitor For The On-demand Treatment Of Hereditary Angioedema

Kalvista Pharmicals宣布了自5月1日起的2025财年的战略计划,其中包括该公司用于按需治疗遗传性血管性水肿的新型口服血浆Kallikrein抑制剂Sebetralstat的战略计划

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发